MODERN APPROACHES TO COMBATING ANTIBIOTIC RESISTANCE

Muhammadiyev Ismail Sulaymonovich
Samarqand davlat tibbiyot universiteti, Pediatriya fakultetining 4-bosqich talabasi
+998910337667 / muxammadievismail767@gmail.com
Muhammadiyev Xamid Anvarovich
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998910327667 / ismail.muxammadiev@icloud.com
Aslamova Kamila O'ktamjonovna
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998973976708 / aslanova1977@icloud.com
Samarova Maftuna Kambarovna
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998906005070 / skmaftuna@icloud.com

Abstract: *Antibiotic resistance (AMR) represents one of the most critical global public health threats of the 21st century, responsible for approximately 1.27 million direct deaths annually worldwide. This review systematically examines contemporary strategies to combat AMR, including antimicrobial stewardship programs (ASPs), novel therapeutic modalities such as bacteriophage therapy and antimicrobial peptides, and international policy frameworks including the WHO Global Action Plan on AMR and the One Health approach. Evidence from randomized controlled trials, systematic meta-analyses, and global surveillance data (WHO GLASS, CDC, ECDC) demonstrates that coordinated multimodal interventions can meaningfully reduce inappropriate antibiotic use and slow resistance emergence. Sustained investment in research and development, robust international surveillance networks, and universal implementation of the One Health framework are essential to turning the tide against AMR.*

Keywords: *antibiotic resistance, antimicrobial resistance (AMR), antimicrobial stewardship, multidrug resistance, bacteriophage therapy, One Health, WHO Global Action Plan*

1. Introduction: Antibiotic resistance (AMR) is one of the most critical global public health challenges of the 21st century. According to the World Health Organization (WHO), antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi. The global burden of AMR is staggering: in 2019, bacterial AMR was directly responsible for approximately 1.27 million deaths worldwide and was associated with an estimated 4.95 million deaths (Murray et al., 2022).

The emergence of multidrug-resistant (MDR) organisms — including methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) — has severely limited treatment options. The inappropriate and overuse of antibiotics in both human medicine and veterinary practice has accelerated the development of resistance mechanisms, including beta-lactamase production, efflux pump upregulation, and target modification (Tacconelli et al., 2018).

This review examines contemporary strategies being developed and implemented globally to address the AMR crisis, including antimicrobial stewardship programs (ASPs), novel therapeutic agents, bacteriophage therapy, and international policy frameworks. Special attention is paid to evidence-based interventions supported by recent clinical and epidemiological data from WHO, CDC, ECDC, and peer-reviewed literature.

2. Main body:

2.1 Epidemiology of Antibiotic Resistance

The global epidemiological landscape of AMR has undergone significant changes over the past decade. A landmark study published in The Lancet (Murray et al., 2022) analyzed data from 204 countries, identifying six critical pathogens responsible for the majority of AMR-associated deaths: Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Sub-Saharan Africa and South Asia bear the highest mortality burden, with standardized rates exceeding 27.3 deaths per 100,000 population.

The European Centre for Disease Prevention and Control (ECDC, 2023) reported that carbapenem-resistant K. pneumoniae isolates accounted for more than 30% of all bloodstream infections in several Southern and Eastern European countries. In the United States, the CDC estimates that more than 2.8 million antibiotic-resistant infections occur annually, resulting in over 35,000 deaths and costing approximately $4.6 billion per year (CDC, 2022).

2.2 Antimicrobial Stewardship Programs (ASPs) : Antimicrobial stewardship programs (ASPs) represent a cornerstone of efforts to combat AMR in healthcare settings. A systematic meta-analysis by Baur et al. (2021) demonstrated that ASP implementation reduced inappropriate antibiotic use by up to 38% and was independently associated with decreased Clostridioides difficile incidence rates in hospital settings. Key ASP components include prospective audit and feedback, formulary restriction with preauthorization, dose optimization using pharmacokinetic/pharmacodynamic (PK/PD) principles, rapid diagnostic integration, and educational interventions.

The integration of clinical decision support systems (CDSS) within electronic health records (EHRs) has enhanced ASP effectiveness, enabling real-time prescribing alerts and automated culture-guided de-escalation recommendations. In low- and middle-income countries, simplified ASP frameworks focusing on empiric therapy guidelines and essential medicine lists have demonstrated feasibility and measurable impact (Mendelson et al., 2020).

2.3 Novel Therapeutic Strategies : Bacteriophage therapy — using viruses that specifically lyse bacteria — has re-emerged as a promising intervention for MDR infections. Case series and compassionate use reports from the United States and Europe have documented clinical success in patients with life-threatening MDR infections treated with personalized phage preparations (Schooley et al., 2021). Randomized controlled trials such as PhagoBurn and PHAGOBIOTIC are currently evaluating efficacy and safety in controlled settings.

Antimicrobial peptides (AMPs) disrupt bacterial membrane integrity through mechanisms distinct from conventional antibiotics, reducing cross-resistance likelihood. Anti-virulence strategies — targeting toxin secretion, biofilm formation, and quorum sensing pathways — represent a fundamentally different paradigm that reduces pathogen fitness without direct bactericidal pressure, potentially limiting selection for resistance (Dickey et al., 2017).

2.4 International Policy and One Health Framework : The WHO Global Action Plan on AMR (2015) established five strategic objectives: improving awareness, strengthening surveillance, reducing infection incidence, optimizing antimicrobial use, and ensuring sustainable investment. By 2024, over 110 nations had developed National Action Plans, though implementation gaps persist in low-income settings. The One Health approach — integrating human, animal, and environmental health — underpins current AMR governance, recognizing that approximately 80% of all antibiotics consumed globally are used in food-animal production (Van Boeckel et al., 2019).

3. Conclusion: Antibiotic resistance represents an urgent and escalating global health emergency demanding immediate, coordinated, and sustained multisectoral responses. Evidence-based antimicrobial stewardship programs remain the most actionable intervention for reducing inappropriate antibiotic use and slowing resistance development in clinical environments. The emerging therapeutic pipeline — encompassing bacteriophage therapy, antimicrobial peptides, anti-virulence compounds, and CRISPR-based tools — provides cautious optimism. Sustainable resolution of the AMR crisis demands universal adoption of the One Health framework, equitable international investment, and political will to implement evidence-based policies across human, animal, and environmental health sectors simultaneously.

REFERECES

1. Murray, C. J. L., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629–655.

2. World Health Organization. (2022). Global antimicrobial resistance and use surveillance system (GLASS) report 2022. WHO Press.

3. Centers for Disease Control and Prevention. (2022). Antibiotic resistance threats in the United States, 2022. U.S. DHHS.

4. European Centre for Disease Prevention and Control. (2023). Antimicrobial resistance in the EU/EEA (EARS-Net): Annual epidemiological report 2022. ECDC.

5. Baur, D., et al. (2021). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria. The Lancet Infectious Diseases, 17(9), 990–1001.

6. Schooley, R. T., et al. (2021). Bacteriophage therapy: a reinvigorated frontier. Antimicrobial Agents and Chemotherapy, 64(10), e01315-20.

7. Dickey, S. W., Cheung, G. Y. C., & Otto, M. (2017). Different drugs for bad bugs: antivirulence strategies. Nature Reviews Drug Discovery, 16(7), 457–471.

8. Tacconelli, E., et al. (2018). Discovery and development of new antibiotics: the WHO priority list. The Lancet Infectious Diseases, 18(3), 318–327.

9. Mendelson, M., et al. (2020). Maximising access to achieve appropriate antibiotic use. The Lancet, 395(10244), 1595–1601.

10. Van Boeckel, T. P., et al. (2019). Global trends in antimicrobial resistance in animals in LMICs. Science, 365(6459), eaaw1944.

11. O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report. Review on Antimicrobial Resistance. https://amr-review.org/

12. WHO. (2021). AWaRe antibiotic book. World Health Organization. https://www.who.int/publications/i/item/9789240013780